Physician profile
Paul Goldstein
NPI 1659428803
$5,444.96
in general payments reported to CMS, 2019-2025
33 companies · $734 in 2025
The $734 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $478 · 2021: $941 · 2022: $925 · 2023: $668 · 2024: $925 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,283 · Education: $44.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.03 |
| Education | $44.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,364.02 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,321.42 | 2019-2025 | Dovato, Apretude, Rukobia |
| Glaxosmithkline, LLC. | $415.21 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $410.52 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Astrazeneca Pharmaceuticals LP | $337.76 | 2019-2025 | Airsupra, Breztri |
| Pfizer INC. | $173.41 | 2019-2025 | |
| Bausch Health US, LLC | $127.82 | 2021-2022 | |
| Esperion Therapeutics, INC. | $106.48 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $106.00 | 2022-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.62 | 2019-2020 | |
| Abbvie INC. | $95.61 | 2021 | |
| Theratechnologies INC. | $94.43 | 2021 | |
| Allergan, INC. | $87.69 | 2019-2020 | |
| Aytu Biopharma, INC. | $85.92 | 2019 | |
| Emd Serono, INC. | $82.00 | 2019-2024 | Serostim |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $71.17 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $52.57 | 2019-2022 | |
| Novo Nordisk INC | $43.49 | 2023-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $42.08 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $37.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.29 | 2023 | Quviviq |
| Amgen INC. | $30.62 | 2024 | Otezla, Repatha |
| Exact Sciences Corporation | $27.16 | 2025 | The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $25.68 | 2019 | |
| Genentech USA, INC. | $23.67 | 2021 | |
| Mylan Institutional INC. | $23.17 | 2019 | |
| Napo Pharmaceuticals INC | $21.64 | 2019 | |
| Circassia INC. | $19.72 | 2019 | |
| Paratek Pharmaceuticals, INC. | $19.54 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.06 | 2022 | |
| Antares Pharma, INC. | $16.29 | 2022 | |
| Almatica Pharma LLC | $14.14 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Acerus Pharmaceuticals Corporation | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.